Posts found in:
Grantees

The Role of Pro-apoptic BCL-2 Family Bid in the DNA Damage Response Programmed cell death, also called apoptosis, is a normal process that the body uses to rid itself of damaged cells. Cancer cells acquire the ability to evade this process, allowing them to live too long, as well as to resist therapeutic treatments such […]

The Role and Targets of APL-specific miRNAs in Leukemogenesis Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), and is characterized by an excess of immature cells called promyelocytes, a form of white blood cells. Dr. Chen has recently found that a set of small RNAs, namely microRNAs, are specifically overexpressed in […]

Specific Targeting of the Leukemia-Associated Antigen FLT3 Using Chimeric Antigen Receptor (CAR)-Engineered NK Cells for Treatment of Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutations Leukemia patients with some mutations routinely relapse and have worse survival. We will engineer immune cells with the ability to specifically bind tumor cells in patients who are resistant to other […]

Therapeutic Targeting of the Oncogenic Ras Pathway in T Cell Leukemia My research group at UCSF focuses on understanding the biochemical signals inside the cell as they occur in developing cells that divide and differentiate. In parallel, we study how cancer cells have abnormal signals, what the composition is of these signals, and how these […]

In Vivo Regulation of Myeloid Cell Development and Leukemia The Rhodes laboratory is using the power of zebrafish genetics to inform on how gene mutation or abnormal activation can affect myeloid cell development and contribute to acute myelogenous leukemia (AML). They have shown that the development of zebrafish myeloid cells is surprisingly similar to humans […]

Genomic Analysis of Familial and Sporadic Chronic Lymphocytic Leukemia

Therapeutic Targeting of the BCL6; p53 axis with Histone Deactylase Inhibitors in Diffuse Large B-Cell Lymphoma Diffuse large B-cell Lymphoma (DLBCL), the commonest form of lymphoma, affects 20,000 people yearly. Bcl6, a critical protein involved in DLBCL, allows cancer cells to grow uncontrollably. p53, another crucial protein, turned off in DLBCL, ordinarily destroys pre-cancerous cells. […]

Diverse Genetic Etiologies Dysregulate the Novel Gene Target, TNK2, in Hematologic Malignancies

Development Context and Germline Variation in Infant Leukemogenesis Infant leukemia is a hard to treat malignancy of childhood with a grim prognosis. The proposed studies will provide insights into how inherited genetic differences among children may predispose to infant leukemia. This will improve our ability to counsel families and treat this disease.

To Collect Peripheral Blood and Bone Marrow Samples from Donors and Recipients of Blood and Marrow Transplants for Laboratory Research In his ongoing studies of anti-leukemia immunity and CTL antigens, Dr. Molldrem has studied myeloid-restricted normal proteins that are highly expressed leukemia. Myeloid leukemias express a number of differentiation antigens associated with granule formation. He […]

Bcl-2 Family Proteins as Metabolic Targets in Leukemia It was established in the early 1900s that cancer cells have increased rates of glucose metabolism. While inhibition of this metabolic program in cancer cells may provide a novel avenue for future cancer treatment, a lack of understanding how metabolic stress can cause cell death has precluded […]

In Vivo Models for Design and Optimization of Targeted Nanocarriers (Protocells) for Leukemia Therapy